1. Volume 93, Issue 6, Pages 1397-1408 (June 2018)
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease 
Peter P. Toth, Jamie P. Dwyer, Christopher P. Cannon, Helen M. Colhoun, Daniel J. Rader, Ashish Upadhyay, Michael J. Louie, Andrew Koren, Alexia Letierce, Jonas Mandel, Maciej Banach 
Kidney International 
Volume 93, Issue 6, Pages (June 2018)
DOI: /j.kint
Copyright © 2018 International Society of Nephrology Terms and Conditions

2. Figure 1
Percentage of changes from baseline to week 24 in (a) LDL-C, (b) apoB, (c) non–HDL-C, (d) triglycerides, (e) Lp(a), and (f) HDL-C by IRF status (intention-to-treat population; pool of eight phase 3 trials). Pool alirocumab 150 versus placebo (with statins): LONG TERM, HIGH FH. Pool alirocumab 75/150 versus placebo (with statins): COMBO I, FH I, FH II. Pool alirocumab 75/100 versus ezetimibe (with statins): COMBO II, OPTIONS I, OPTIONS II. Adjusted means (SE) taken from multiple imputation followed by robust regression. Interaction P values compare the LDL-C percentage of reduction (difference vs. control) for the IRF and without IRF subgroups. IRF were defined based on medical history: with IRF included those with eGFR 30–59 ml/min per 1.73 m2, without IRF included those with eGFR 60–89 ml/min per 1.73 m2, and eGFR ≥90 ml/min per 1.73 m2. ALI, alirocumab; Apo, apolipoprotein; CI, confidence interval; eGFR, estimated glomerular filtration rate; EZE, ezetimibe; IRF, impaired renal function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; PBO, placebo.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

3. Figure 1
Percentage of changes from baseline to week 24 in (a) LDL-C, (b) apoB, (c) non–HDL-C, (d) triglycerides, (e) Lp(a), and (f) HDL-C by IRF status (intention-to-treat population; pool of eight phase 3 trials). Pool alirocumab 150 versus placebo (with statins): LONG TERM, HIGH FH. Pool alirocumab 75/150 versus placebo (with statins): COMBO I, FH I, FH II. Pool alirocumab 75/100 versus ezetimibe (with statins): COMBO II, OPTIONS I, OPTIONS II. Adjusted means (SE) taken from multiple imputation followed by robust regression. Interaction P values compare the LDL-C percentage of reduction (difference vs. control) for the IRF and without IRF subgroups. IRF were defined based on medical history: with IRF included those with eGFR 30–59 ml/min per 1.73 m2, without IRF included those with eGFR 60–89 ml/min per 1.73 m2, and eGFR ≥90 ml/min per 1.73 m2. ALI, alirocumab; Apo, apolipoprotein; CI, confidence interval; eGFR, estimated glomerular filtration rate; EZE, ezetimibe; IRF, impaired renal function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; PBO, placebo.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

4. Figure 2
Percentage of change in low-density lipoprotein cholesterol from baseline to week 24 according to baseline proteinuria status (intention-to-treat population; pool of ten phase 3 trials). LS means and SE taken from mixed-effects model with repeated-measures analysis. CI, confidence interval; LS, least squares.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

5. Figure 3
Percentage of change from baseline of lipoproteins over time by IRF status in 2 trials using alirocumab 150 mg Q2W versus placebo (a) LDL-C, (b) apoB, (c) non–HDL-C, (d) triglycerides, (e) Lp(a), and (f) HDL-C (intention-to-treat population). Alirocumab 150 mg Q2W: LONG TERM, HIGH FH. ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; IRF, impaired renal function; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

6. Figure 4
Mean estimated glomerular filtration rate (eGFR) values over time by impaired renal function (IRF) status (safety population, pool of eight phase 3 trials).
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions